Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Last week, Novo Nordisk released its year-end results ... The company has, however, been working on a weight loss pill, which could be a game-changer for the market. Whichever healthcare business ...

Learn More » Last week, Novo Nordisk released its year-end results ... The company has, however, been working on a weight loss pill, which could be a game-changer for the market.

A pill. Novo Nordisk already makes semaglutide, a tablet used to treat patients with Type 2 diabetes. However, they are seeking regulatory approval for the tablet to be used as a weight loss ...

Novo Nordisk's stock (NVO ... The highest dose, 20 mg, provided the highest weight loss. Novo is also testing a pill with the same formula, which had disappointing results in early-stage trials ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...